Lastly, the 5′ cap of SARS CoV-2 is recognized by Eukaryotic initiation factor 4A-1 (EIF4A1) [76] and is known to be significantly increased in the platelet proteome of COVID-19 patients thought to affect viral replication and downstream activation of platelets, resulting in thrombotic microangiopathy and increased mortality [77]. This evidence concerns the gene EIF4A1 and Genetic thrombotic microangiopathy.